Royal Sense Ltd launches Stergic Dengue IgG/IgM Rapid Test

Royal Sense Limited has announced the official launch of our latest In Vitro Diagnostics Product, the Stergic Dengue IgG/IgM Rapid Test detects dengue virus antibodies in blood for quick diagnosis of current or past infection.

The Dengue IgG/IgM Rapid Test is a diagnostic tool used to detect antibodies against the dengue virus in blood samples. This test helps differentiate between a recent dengue infection (IgM positive) and a past infection (IgG positive). The test involves a simple procedure: a small blood sample is collected, usually via fingerstick, and then applied to a test strip or cassette. Results are typically available within 15-20 minutes. This rapid test is useful for early diagnosis in areas where dengue is prevalent and can guide appropriate treatment. However, it's important to confirm results with more specific tests or clinical evaluation, especially in cases of indeterminate or conflicting results.

Royal Sense Limited is a leading provider of innovative diagnostic solutions for healthcare professionals worldwide. With a focus on quality, reliability, and accessibility, we are dedicated to improving patient care and advancing the field of medical diagnostics.

Shares of Royal Sense Limited was last trading in BSE at Rs. 140.00 as compared to the previous close of Rs. 135.00. The total number of shares traded during the day was 2000 in over 1 trades.

The stock hit an intraday high of Rs. 140.00 and intraday low of 140.00. The net turnover during the day was Rs. 280000.00.

Source : Equity Bulls

Keywords

RoyalSense MedicalEquipment INE0QQG01019 InVitroDiagnosticsProduct DengueRapidTest